CenturyLink Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

CenturyLink Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-7,899	Closed	-$386K	–	238
2016 Q2	$386K	Sell	7,899 -2,509	-24%	-$162K	0.14%	170
2016 Q1	$659K	Buy	10,408 +5,424	+109%	+$355K	0.24%	142
2015 Q4	$559K	Sell	4,984 -204	-4%	-$20.4K	0.2%	159
2015 Q3	$500K	Buy	+5,188	New	+$594K	0.16%	165

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CenturyLink Investment Management's RARE Position: Q3 2016 in Review

CenturyLink Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2016, closing a stake of 7,899 shares — an estimated $386K sold.

CenturyLink Investment Management first reported a position in RARE in Q3 2015 and held it in 4 quarters. The position peaked at $659K in Q1 2016. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2016.

CenturyLink Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2016 after selling out during the quarter.
CenturyLink Investment Management sold 7,899 Ultragenyx Pharmaceutical shares in Q3 2016, an estimated $386K.
CenturyLink Investment Management first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 4 quarters.
CenturyLink Investment Management's Ultragenyx Pharmaceutical position peaked at $659K in Q1 2016.
172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2016.

Based on CenturyLink Investment Management's 13F filing for Q3 2016, filed 12 Oct 2016.